Onconetix (NASDAQ:ONCO) Issues Earnings Results

Onconetix (NASDAQ:ONCO) announced its quarterly earnings data on Friday. The company reported $12.58 EPS for the quarter, FiscalAI reports. Onconetix had a negative return on equity of 632.63% and a negative net margin of 4,011.43%.The business had revenue of $0.30 million during the quarter.

Onconetix Price Performance

Shares of Onconetix stock opened at $0.54 on Friday. Onconetix has a 1 year low of $0.44 and a 1 year high of $14.86. The firm has a market cap of $841,805.00, a price-to-earnings ratio of 0.05 and a beta of 3.51. The company has a 50-day moving average of $1.17 and a 200 day moving average of $2.22.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. acquired a new position in Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors and hedge funds.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.